Venus Concept Inc. announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AI.ME next generation robotic technology for fractional skin resurfacing. The AI.ME robotic system utilizes an advanced visualization system, machine vision, and Artificial Intelligence algorithms to target the dermis in a pre-planned selective, and predictable manner. It uses a smart array of micro-coring hollow punches to precisely core and excise micro-skin fractions at a precise depth to remove up to 10% of skin in the treatment area, leading to collagen deposition and fractional skin resurfacing of the treated area.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.684 USD | -11.04% | -16.04% | -42.01% |
Apr. 08 | Venus Concept Inc. Announces Israeli Regulatory Approval for Venus Bliss MAX | CI |
Apr. 01 | Transcript : Venus Concept Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.01% | 4.89M | |
+7.88% | 218B | |
+6.13% | 182B | |
+11.77% | 132B | |
+26.79% | 108B | |
+13.54% | 52.98B | |
-1.89% | 47.59B | |
-0.94% | 39.96B | |
+11.12% | 39.22B | |
+24.78% | 26.94B |
- Stock Market
- Equities
- VERO Stock
- News Venus Concept Inc.
- Venus Concept Receives 510(k) Clearance from U.S. FDA for Use of its AI.ME Next Generation Robotic Technology for Fractional Skin Resurfacing